MedPath

Study of Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir in HIV-infected Antiretroviral naïve Subjects

Phase 3
Completed
Conditions
HIV Infections
Interventions
Drug: darunavir/r QD + tenofovir/emtricitabine QD (fixed dose combination)
Drug: darunavir/ritonavir QD + raltegravir BID
Registration Number
NCT01066962
Lead Sponsor
ANRS, Emerging Infectious Diseases
Brief Summary

The triple therapy darunavir/r + tenofovir/emtricitabine is likely to become a relevant first-line treatment option in the years to come. The dual combination of boosted darunavir + raltegravir is an innovative treatment option that combines two potent new antiretroviral drugs, one of which belongs to a new drug class (integrase inhibitor). The expected efficacy profile of this combination is promising. Moreover, this combination might have a better tolerance profile and has the advantage of sparing the NRTI class.

In the context of tenofovir/emtricitabine currently being a reference backbone in first-line antiretroviral regimens, we hypothesise that, in combination with darunavir/r, raltegravir may be an alternative option if its efficacy is non-inferior to tenofovir/emtricitabine.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
800
Inclusion Criteria
  • Patient with confirmed HIV infection
  • Age ≥ 18 years
  • Written informed consent
  • Male patient or non-pregnant, non-lactating female
  • No previous treatment with any antiretroviral drugs
  • HIV-1 RNA > 1000 copies/ml
  • Indication to start an antiretroviral treatment as long as subject has also a CD4 cell count ≤ 500/mm3 either at screening or on a sample taken within 3 months before screening
  • No major IAS-USA mutations on genotypic testing at the screening visit or on any historical genotype, if available

Non-inclusion Criteria:

  • Woman without effective contraception method (recommended contraception during the trial is mechanical + a second method other than an oral contraceptive)
  • Pregnant or breastfeeding woman
  • Woman expecting to conceive during the study
  • HIV-2 co-infection
  • Creatinine clearance < 60 ml/mn (Cockcroft & Gault equation), alkaline phosphatase, ASAT, or ALAT ≥ 5 ULN
  • Patient with significant impairment of hepatic function, defined as serum albumin < 2.8 g/dl or INR > 1.7 or presence of ascites, in the absence of another explanation for the abnormal finding
  • CD4 > 500/mm3 at screening, except in case of symptomatic HIV disease (defined by conditions qualifying for CDC category B or C) or CD4 ≤ 500/mm3 on a sample taken within 3 months before screening.
  • Any major IAS-USA mutation conferring resistance to one or more of reverse transcriptase or protease inhibitors on genotypic testing at screening
  • Mycobacteriosis under treatment
  • Malignancy requiring chemotherapy or radiotherapy
  • Positive HBs Ag
  • HCV infection for which specific treatment is ongoing or planned during the first year on trial treatment
  • Known hypersensitivity to one of the trial drugs or its excipients
  • Contraindicated concomitant treatment
  • Anticipated non-compliance with the protocol
  • Participation in another clinical trial with an on-going exclusion period at screening
  • Subject under legal guardianship or incapacitation
  • Subject, who in the opinion of the investigator, is unable to complete the study period
Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
darunavir/r + tenofovir/emtricitabinedarunavir/r QD + tenofovir/emtricitabine QD (fixed dose combination)-
darunavir/r + raltegravirdarunavir/ritonavir QD + raltegravir BID-
Primary Outcome Measures
NameTimeMethod
Time to virologic or clinical failure, as the first occurrence of one of six protocol-defined componentsminimum 2 years
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (77)

Torvergata University

🇮🇹

Rome, Italy

Hospital Clinic

🇪🇸

Barcelona, Spain

University of Brescia

🇮🇹

Brescia, Italy

Ospedale Santa Maria Annunziata

🇮🇹

Florence, Italy

Luigi Sacco Hospital

🇮🇹

Milano, Italy

Hôpital Gustave Dron

🇫🇷

Tourcoing, France

Gemeinschaftspraxis Jessen-Jessen-Stein

🇩🇪

Berlin, Germany

Laikon General Hospital

🇬🇷

Athens, Greece

Hospital de la Santa Creu I Sant Pau.

🇪🇸

Barcelona, Spain

Hospital Germans Trias i Pujol

🇪🇸

Barcelona, Spain

Med. Universitätsklinik I

🇩🇪

Bonn, Germany

Ospedale "Amedeo di Savoia"

🇮🇹

Turin, Italy

Saint Thomas hospital

🇬🇧

London, United Kingdom

Hôpital La Pitié Salpétrière

🇫🇷

Paris, France

San Paolo Hospital

🇮🇹

Milan, Italy

Hôpital Foch

🇫🇷

Suresnes, France

Royal Bournemouth Hospital

🇬🇧

Bournemouth, United Kingdom

Sahlgrenska hospital

🇸🇪

Gothenburg, Sweden

Western General Hospital

🇬🇧

Edinburgh, United Kingdom

Hospital General Universitario de Alicante

🇪🇸

Alicante, Spain

Saint Stephen's Centre

🇬🇧

London, United Kingdom

Hospital Carlos III

🇪🇸

Madrid, Spain

Sapienza Universita di Roma

🇮🇹

Rome, Italy

Fondazione Centro San Raffaele del Monte Tabor

🇮🇹

Milan, Italy

Istituto Naziona e per le Malattie "Lazzaro Spallanzani"

🇮🇹

Rome, Italy

Hôpital Bicêtre

🇫🇷

Le Kremlin Bicêtre, France

Hôpital Gui de Chauliac

🇫🇷

Montpellier, France

Hôpital Purpan

🇫🇷

Toulouse, France

Medizinische Hochschule Hannover

🇩🇪

Hannover, Germany

Universitätsklinik Köln

🇩🇪

Köln, Germany

Hospital del Mar

🇪🇸

Barcelona, Spain

Hospital Gregorio Marañon

🇪🇸

Madrid, Spain

Otto Wagner Spital mit Pflegezentrum

🇦🇹

Wien, Austria

UZ Gent

🇧🇪

Gent, Belgium

Rigshospitalet

🇩🇰

Copenhagen, Denmark

Hôpital Pellegrin

🇫🇷

Bordeaux, France

Hôpital Saint André

🇫🇷

Bordeaux, France

Hôpital Pierre Zobda-Quitman

🇫🇷

Fort de France, France

Hvidovre Hospital

🇩🇰

Hvidovre, Denmark

Hôpital Henri Mondor

🇫🇷

Créteil, France

Hôpital du Bocage

🇫🇷

Dijon, France

CHD de la Roche sur Yon

🇫🇷

La Roche sur Yon, France

Hôpital Bichat

🇫🇷

Paris, France

Hôpital Européen Georges Pompidou (HEGP)

🇫🇷

Paris, France

Hôpital de l'Hôtel Dieu

🇫🇷

Nantes, France

Hôpital Saint Louis

🇫🇷

Paris, France

Hôpital Saint Antoine

🇫🇷

Paris, France

Hôpital Pontchaillou

🇫🇷

Rennes, France

ICH study centre

🇩🇪

Hamburg, Germany

Asklepios-Klinik St. Georg

🇩🇪

Hamburg, Germany

Klinikum der Johann Wolfgang Goethe Universität

🇩🇪

Frankfurt, Germany

Universitätsklinikum Essen

🇩🇪

Essen, Germany

Saint Laszlo Hospital

🇭🇺

Budapest, Hungary

Hospital Santa Maria

🇵🇹

Lisbon, Portugal

Attikon University Hospital

🇬🇷

Athens, Greece

Evaggelismos General Hospital

🇬🇷

Athens, Greece

Mater Misericordiae

🇮🇪

Dublin, Ireland

Hospital of Infectious Diseases of Warsaw

🇵🇱

Warsaw, Poland

AMC

🇳🇱

Amsterdam, Netherlands

Hospital Clinico San Carlos

🇪🇸

Madrid, Spain

Hospital Universitario La Paz

🇪🇸

Madrid, Spain

Hospital Universitario La Fe

🇪🇸

Valencia, Spain

Hospital Universitario Virgen de la Victoria

🇪🇸

Malaga, Spain

Karolinska hospital

🇸🇪

Stockholm, Sweden

Southmead Hospital

🇬🇧

Bristol, United Kingdom

Venhälsan hospital

🇸🇪

Stockholm, Sweden

Saint Mary's hospital

🇬🇧

London, United Kingdom

Royal Free Hospital

🇬🇧

London, United Kingdom

Mortimer market centre

🇬🇧

London, United Kingdom

ITZ Antwerpen

🇧🇪

Antwerpen, Belgium

Jan van Goyen Medical Center

🇳🇱

Amsterdam, Netherlands

Rijnstate Hospital

🇳🇱

Arnhem, Netherlands

Hospital de Joaquim Urbano

🇵🇹

Porto, Portugal

Allgemeines Krankenhaus der Stadt Wien

🇦🇹

Wien, Austria

Hospital de Curry Cabral

🇵🇹

Lisbon, Portugal

CHU Saint Pierre

🇧🇪

Brussels, Belgium

St James's Hospital

🇮🇪

Dublin, Ireland

© Copyright 2025. All Rights Reserved by MedPath